Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) – Analysts at HC Wainwright dropped their Q2 2027 earnings per share estimates for shares of Genmab A/S in a research note issued to investors on Friday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.44 per share for the quarter, down from their prior estimate of $0.59. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share.
A number of other equities research analysts have also recently issued reports on the stock. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Morgan Stanley lifted their target price on shares of Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Friday, October 30th. TD Cowen lifted their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Weiss Ratings raised shares of Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Finally, JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $53.61.
Genmab A/S Trading Down 3.1%
GMAB stock opened at $54.07 on Monday. The company has a market capitalization of $33.74 billion, a PE ratio of 42.92, a price-to-earnings-growth ratio of 2.25 and a beta of 0.73. Genmab A/S has a one year low of $23.62 and a one year high of $59.97. The company’s 50 day moving average price is $40.05 and its two-hundred day moving average price is $31.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.43 and a current ratio of 2.45.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.36 by $0.20. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in GMAB. Renaissance Technologies LLC boosted its position in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares during the period. First Trust Advisors LP grew its holdings in Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,126,069 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of Genmab A/S by 8.0% in the third quarter. Pictet Asset Management Holding SA now owns 1,150,854 shares of the company’s stock valued at $41,044,000 after acquiring an additional 84,927 shares during the period. Quantinno Capital Management LP increased its position in shares of Genmab A/S by 14.4% in the first quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock valued at $7,579,000 after acquiring an additional 35,588 shares during the period. Finally, Royal Bank of Canada increased its position in shares of Genmab A/S by 1.8% in the first quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock valued at $4,029,000 after acquiring an additional 2,637 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S News Roundup
Here are the key news stories impacting Genmab A/S this week:
- Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 price target, above the share price in the supplied market data. MarketBeat report
- Neutral Sentiment: Genmab disclosed an increase of 164,828 shares following employee warrant exercises. The issuance creates some dilution, though the announcement does not indicate its likely financial impact. Capital increase announcement
- Neutral Sentiment: Genmab reported managerial and associated-person transactions, but the supplied notice provides no transaction details to indicate whether they were purchases or sales. Managerial transaction announcement
- Negative Sentiment: HC Wainwright cut several quarterly and annual EPS forecasts, including its FY2027 estimate to $1.60 from $2.15. The firm still rates the stock Buy, but the downward revisions could pressure sentiment.
- Negative Sentiment: Reported short interest rose 46.4% from mid-October to 9.66 million shares as of October 30, suggesting increased bearish positioning. It was still about 1.6% of shares, with a 1.2-day short-interest ratio.
Genmab A/S Company Profile
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
